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MaAtrial ﬁbrillation (AF) ablation is widely performed and is progressively supplanting drug therapy. Catheter-based AF
ablation modalities have evolved progressively in parallel to our understanding of underlying mechanisms. Initial attempts
tomimic the surgicalmaze procedure, whichwere based on themultiplewaveletmodel, failed because of adverse outcomes
and insufﬁcient effectiveness. A major advance was the targeting of pulmonary veins, which is highly effective for
paroxysmal AF. Active research on the underlying mechanisms continues. The main challenge is reconnection, but
procedures tominimize this are being developed. Ablation procedures for persistent AF are presently limited by suboptimal
success rates and long-term disease progression that causes recurrences. Basic research into the underlying mechanisms
has led to promising driver mechanism-directed clinical approaches along with pathways toward the prevention of atrial
remodeling. Here, we review the role of basic research in the development of presently used AF-ablation procedures and
look toward future contributions in improving outcomes. (J Am Coll Cardiol 2014;64:823–31) © 2014 by the American
College of Cardiology Foundation.A trial ﬁbrillation (AF), the most commonsustained cardiac arrhythmia, has complexunderlying mechanisms (1). The incidence
and prevalence of AF are increasing as the population
ages (2). By the mid-1990s, ablation had revolution-
ized the therapy of most cardiac arrhythmias, with
the notable exceptions of AF and ventricular tachy-
cardias (3). The subsequent development of success-
ful AF ablation procedures has dramatically changed
AF management, but many limitations remain (4).
The evolution of AF ablation has been marked by
dynamic feedback between basic science concepts
and clinical observations, each at various times
contributing to advances in the other (Fig. 1). This
paper reviews the fundamental science related to AF
ablation, discussing the basic knowledge that led to
advances in ablation procedures, ﬁndings emanating
from clinical observations that forced a return to the
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provements in our understanding of underlying
mechanisms (Central Illustration).
BASIC RESEARCH AND THE
EARLIEST AF ABLATION PROCEDURES
Multiple basic mechanisms (Fig. 2) were recognized as
potential contributors to AF in the early 20th century
(1,5). However, following Gordon Moe’s classic work
(6), the multiple wavelet hypothesis (Fig. 2A) pre-
dominated. Themultiple wavelet hypothesis provided
a quantitative framework for Garrey’s much earlier
idea (5) that the persistence of ﬁbrillation depends on
a critical mass of tissue large enough to support
multiple re-entrant waves that prevent simultaneous
termination of all underlying re-entrant activity.
Translation of this paradigm (Fig. 1A) to humans
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FIGURE 1 Schematic of the In
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CFAE = complex fractionated
atrial electrogram
DF = dominant frequency
(of fast-Fourier transformed
signals)
ERP = effective refractory
period
GP = ganglionated plexus
LA = left atrium/atrial
PV = pulmonary vein
PVI = pulmonary vein isolation
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824procedure (7) (Fig. 1B), arguably the single
most successful nonpharmacological ap-
proach to sinus rhythm maintenance for AF
(“arguably” because the quoted success rates
for the maze procedure are on the basis of
symptomatic recurrences, and many AF re-
currences are asymptomatic). The ﬁrst
catheter-based ablation approaches for AF
(Fig. 1C) were designed to mimic the surgical
cut-and-sew maze procedure (8–10). This ﬁrst
phase of AF ablation largely failed because
right atrial–directed ablations were generally
insufﬁcient to control the arrhythmia, trans-
mural linear lesions proved very difﬁcult to
achieve, and left atrial (LA) procedures wereassociated with an unacceptable risk of major com-
plications, particularly stroke (10).
THE ROLE OF PULMONARY VEINS AND
OTHER KEY ANATOMICAL STRUCTURES
A key discovery in the development of AF ablation
was the recognition by Haissaguerre et al. (11) of theterplay Between Basic Understanding and
atrial ﬁbrillation (AF) (A) led to the highly-successful
wever, attempts at mimicking the surgical maze by
(C). Clinical identiﬁcation of the key role played by the
e ﬁrst truly successful ablation procedures for AF (D) and
g mechanisms (E). Limited success of PV ablation for
xamination of other mechanisms and mechanism-targeted
procedures are labeled in red, basic research contributionsrole of pulmonary vein (PV) cardiomyocyte sleeves in
AF, which led to a variety of PV-directed ablation
approaches (Fig. 1D). Because the mechanisms for PV
participation in AF were unclear, investigators began
to address them (Fig. 1E). Initially, the role of the PVs
was attributed to well-localized, spontaneous focal
ectopic driver activity, which was supported by
observations of dramatic resolution of AF with local
radiofrequency (RF) energy application in a PV.
However, it soon became apparent that AF tended to
recur because other sources in the same and other
PVs emerged, and pulmonary vein isolation (PVI)
rapidly replaced focal ablation (12). Basic studies had
identiﬁed spontaneous PV activity in the early 1980s,
but the ﬁring rate was slow and unlikely to contribute
to AF (13).
Following the report by Haissaguerre et al. (11),
basic scientists noted rapid arrhythmic activity
in rabbit PVs (14) and provided evidence of Ca2þ
mishandling in canine PVs (15). However, other ob-
servations in dogs failed to support the idea that
normal PV sleeve cardiomyocytes spontaneously
generate rapid focal activity (16–18). Moreover, PV
cardiomyocytes displayed action potential (AP)
properties (short AP duration and decreased phase
0 upstroke velocity) that reduce refractoriness
and conduction velocity, potentially promoting re-
entry (17). In addition, structural properties of PV
cardiomyocyte sleeves, including longitudinal disso-
ciation and abrupt shifts in ﬁber orientation, also
favored local conduction slowing, block, and re-entry
(19,20). A mathematical model incorporating realistic
PV cellular electrophysiology and coupling properties
suggested that there was enhanced vulnerability to
local re-entry (21). This model was recently corrobo-
rated in the clinical electrophysiology laboratory (22).
Present evidence suggests that multiple features of
the PV cardiomyocyte sleeve predispose it to either
focal or re-entrant activity, with discrete roles in
AF initiation and maintenance in speciﬁc patient
populations (23).
PVI was soon noted to be much more effective
for paroxysmal than persistent AF (24). Subsequent
work showed that non-PV sources become more
important as AF becomes more persistent (25).
Similarly, in animal models of persistent AF, the PVs
play a limited role in AF maintenance (26). To deal
more effectively with persistent AF, investigators
sought other key anatomical structures and mecha-
nisms involved in AF maintenance. Multiple linear
lesions were found to suppress AF induced by vagal
stimulation (27) and long-term rapid atrial pacing,
with (28) or without (29) associated mitral regurgi-
tation in dogs.
CENTRAL ILLUSTRATION Pathophysiology Schema of Atrial Fibrillation
This schematic illustrates the interactions between basic science concepts and clinical
catheter-based AF-ablation techniques. The prevailing mechanistic hypothesis used to
explain AF until the late 1990s was multiple circuit re-entry. The successful surgical maze
procedure was based on this concept, and led to the catheter-based maze procedure,
which failed because of complications and inadequate efﬁcacy. The ﬁrst successful AF
ablation procedures resulted from a clinical recognition of the role of the PVs in AF. This
observation led to a return to the bench to address the basic mechanisms by which the
PVs contribute to AF occurrence, as well as a broader range of related fundamental
mechanisms. Advances in the basic mechanistic understanding of AF have led to a variety
of ablation approaches that target underlying mechanisms and promise to greatly improve
the success of AF ablation. PV ¼ pulmonary vein.
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825A variety of anatomical structures have been
speciﬁcally targeted in clinical approaches to
persistent AF (Fig. 3). Stepwise ablation, in which
discrete areas are targeted sequentially to an AF
maintenance endpoint, such as AF termination (30),
is a common paradigm. The LA posterior wall and
roof regions have unique characteristics that
contribute to AF maintenance. Shorter cycle lengths
are found in the posterior LA during persistent AF
in a canine model; cryoablation of this region sup-
presses AF (31). Experimental ablation of the LA roof
suppresses AF perpetuation by interrupting LA re-
entry circuits (26); however, macrore-entry atrial
tachycardias sometimes result. Macrore-entry tachy-
cardias also plague clinical AF procedures, particu-
larly stepwise approaches involving multiple linear
lesions (32). Other important atrial structures have
also been identiﬁed in animal studies, including the
atrial septum (33), Bachmann’s bundle (33), and the
ligament of Marshall (34). The stepwise approach to
functionally-important atrial structures produced
some improvement in persistent AF ablation, but
failure rates and iatrogenic arrhythmias continue to
be problems.
THE ROLE OF
AUTONOMIC NERVOUS SYSTEM STRUCTURES
It has long been recognized that the autonomic
nervous system plays an important role in governing
AF susceptibility (35). Cervical vagal-nerve stimula-
tion promotes long-lasting AF by abbreviating the
atrial effective refractory period in a spatially het-
erogeneous manner (36,37). Cholinergic stimulation
stabilizes AF-maintaining rotors (38). Depending on
tissue properties and geometry, vagal AF may be
maintained by single rotors or complex functional
multicircuit re-entry (39). Adrenergic stimulation
promotes AF by enhancing triggered activity (40). In
some pathological contexts, adrenergic activation is
essential for the emergence of atrial ectopic activity
(41). Autonomic neural activity induces Ca2þ-
dependent atrial tachyarrhythmias in canine models
(42–44), and stellate-ganglion cryoablation delays
tachyarrhythmia development (44). Cardiac auto-
nomic inputs pass through epicardial fat pads to form
ganglionated plexuses (GPs), containing both sympa-
thetic and parasympathetic components (40,45).
Ablation of cardiac GPs suppresses vagal AF (46,47).
The effectiveness of GP ablation in other AF models
is model-speciﬁc: atrial tachycardia remodeling
produces autonomic hyperinnervation, and GP abla-
tion has substantial anti-AF effects in tachycardia-
remodeled dogs; however, experimental heart failurecauses denervation, and GP ablation has no effect on
AF associated with heart failure (48). Experimental
sleep apnea induces spontaneous AF following
increased GP ﬁring, and GP ablation suppresses apnea-
related AF inducibility (49).
Because most of the important GPs are situated
near the PV ostia, autonomic denervation may
contribute to the efﬁcacy of PVI procedures (47), as
evidenced by lower recurrence rates with PVI pro-
ducing autonomic denervation (50). A controlled
clinical study suggested that combining GP ablation
with circumferential PVI prevents paroxysmal AF
recurrence (51); however, it is uncertain whether the
beneﬁt was truly due to autonomic denervation or
simply to more extensive lesion sets. One limitation
to autonomic denervation approaches is spontaneous
reinnervation, occurring over months in animal
models (52,53) and apparently in humans (50). If GP
ablation is to provide long-term beneﬁt, ways to
FIGURE 3 Key Anatomical Structures and Common AF Ablation Sites
This schematic illustrates various key anatomical structures that have been shown to play
signiﬁcant roles in AF, and have been targeted for ablation. Principal sites that have been
included in AF ablation procedures are shown in color. The orange boxes indicate regions
that have been targeted for cardiac autonomic innervation (ganglionated plexus) ablation.
For more detailed discussion see text. CS ¼ coronary sinus; GP ¼ ganglionated plexus;
LA ¼ left atrial; LAA ¼ left atrial appendage; LOM ¼ ligament of Marshall; LPV ¼ left
pulmonary vein; PV ¼ pulmonary vein; RAA ¼ right atrial appendage; RPV ¼ right
pulmonary vein.
FIGURE 2 Three Major Candidate Mechanisms for AF
This ﬁgure schematically illustrates 3 basic concepts of the mechanism maintaining AF.
Each concept is based on a primary “driver” mechanism, shown in red in each panel.
Interestingly, the basic concepts represented were ﬁrst put forward in the early 20th
century (for discussion see reference 1). (A) Multiple circuit re-entry. (B) Focal-ectopic
drivers. (C) Rotor sources. Driver mechanisms are shown in red. LA ¼ left atrium;
PV ¼ pulmonary vein; RA ¼ right atrium.
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A recent study showed that PVI plus GP ablation
provided modestly (but statistically-signiﬁcantly)
improved sinus rhythm maintenance over PVI plus
linear ablation (54).
Renal sympathetic denervation has generated
considerable excitement as an approach for managing
resistant hypertension (55). Both clinical studies (56)
and experimental data (57,58) have suggested that
there is AF protection following renal sympathetic
denervation. However, the carefully conducted,
sham denervation-controlled, SIMPLICITY HTN-3
trial failed to document any beneﬁt from renal
denervation in resistant hypertension (59), raising
doubts about the procedure.
DYNAMICAL PROPERTIES OF ATRIAL
ACTIVITY AND ABLATION TARGETS
The term dynamical is often applied to describe
time-dependent properties, in particular those that
concern the relationship between each event in a
series and the preceding event. Atrial dynamical
properties that relate to the development and
maintenance of atrial tachyarrhythmias have been
exploited to guide AF ablation (Fig. 4).
PROPERTIES OF LOCAL ATRIAL ELECTRICAL
ACTIVITY AS GUIDES TO AF ABLATION
The targeting of sites with complex fractionated atrial
electrograms (CFAEs) (Fig. 4A) was initially reported
to produce very high success rates in clinical AF (60).
Extensive subsequent work was performed to
understand the mechanisms underlying CFAEs,
their relationship to the AF substrate, and the precise
value of CFAE targeting. CFAEs may relate to
ﬁbrosis-associated focal conduction delays at rotor
anchoring-points (61) or wave fractionation caused by
rotor meandering (62). Noncontact mapping in dogs
suggests that, rather than emerging from true
arrhythmia driver sites, most CFAE activity may
result from wave front collision (63). Autonomic
mechanisms may also be involved (64). The available
basic research suggests that CFAEs are produced by a
variety of mechanisms, with more or less direct re-
lationships to the primary AF-maintaining substrate.
Very few centers presently target CFAEs only,
although many include CFAE targeting in persistent
AF ablation protocols. A recent meta-analysis sug-
gested that adding CFAE-targeted lesions to PVI re-
duces AF recurrence by about one-third in persistent
AF without marginal beneﬁt in paroxysmal AF, at the
expense of longer procedures and increased risks of
post-ablation atrial tachycardias (65).
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FIGURE 4 Dynamical Atrial Tissue Electrophysiological Properties
Relevant to AF Ablation
(A) Complex fractionated atrial electrograms (CFAEs) are often targeted in ablation pro-
cedures for persistent AF. (B) Atrial electrogram activity and corresponding fast-Fourier
transformation with dominant frequency (DF) indicated. Zones with the greatest DF values
are targeted with the assumption that they are driver regions. (C) Restitution properties.
(Left) Action potential duration (APD) restitution. When the slope of the relationship
between APD and the preceding diastolic interval (DI) exceeds 1, the APD change resulting
from a change in DI will be greater than the change in DI, causing progressive ampliﬁcation
in changes, instability, and arrhythmia initiation. (Right) Conduction restitution. Reprinted
with permission from Narayan et al. (76). A ¼ atrial electrogram; AT ¼ activation time;
CSmid ¼ coronary sinus electrogram; DF ¼ dominant frequency; LSPV ¼ left superior
pulmonary vein; MAP ¼ monophasic action potential; PV ¼ pulmonary vein; S1 ¼ basic
stimulus; S2 ¼ extrastimulus.
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827DOMINANT-FREQUENCY ANALYSIS
An early experimental study introduced the concept
of AF drivers: rapidly-ﬁring regions that maintain the
arrhythmia (31). Mechanistically, either focal ectopic
sources (Fig. 2B) or rapid local re-entry (Fig. 2C)
might underlie driver activity. Dominant frequency
(DF) analysis (Fig. 4B) was introduced to identify
rapidly-discharging periodic sources showing maxi-
mum DFs (DFmax) that might be AF drivers (66).
Left-to-right atrial DF gradients are consistent with
a primary role of the LA in AF maintenance
(67,68), and studies of tissues from AF patients have
provided insights into potential ionic mechanisms
(69). One study showed that DFmax-targeted ablation
improved outcomes when signiﬁcant reductions
in DFs and left-to-right atrial DF gradient were ach-
ieved (70), but a subsequent study (71) showed little
beneﬁt from DF targeting and limited correlations
between DFmax and CFAE sites. A recent detailed
analysis showed that focal DFmax areas are less
common in persistent versus paroxysmal AF, are
spatially unstable, and, in many cases, cannot be
identiﬁed with localized drivers (72).
RESTITUTION PROPERTIES AND ROTORS
Dynamical properties, such as the response of the
AP to premature activation and increased activa-
tion rates (Fig. 4C), contribute to AF vulnerability
(73,74). Abnormalities in Ca2þ handling are important
in abnormal rate adaptation (73). Steep AP dura-
tion restitution favors the initiation of re-entrant
arrhythmias (74), and may help to identify appro-
priate sites for intervention (75). Electrical restitution
properties of atrial tissue (76) were recently incorpo-
rated in computational algorithms to identify AF
driver mechanisms in patients (77).
The concept of “spiral-wave re-entry” (Fig. 5) has
signiﬁcant implications for AF. Initially developed by
Winfree (78,79), spiral-wave re-entry differs in some
important ways from the “leading circle” paradigm
initially developed by Allessie et al. (80). Rotor is a
descriptive term for a spiral-wave re-entry generator.
Rotors can be long lasting and stable, or transient and
enduring as brieﬂy as a single rotation.
NOVEL MAPPING-METHODS AND
MECHANISM-DIRECTED ABLATION
Arguably, one of the greatest contributions of basic
research to AF ablation is the recent development of
mechanism-directed approaches (Fig. 1F). The idea of
targeting the patient-speciﬁc substrate underlying AF
emerged from basic research over a decade ago (81),but only recently have tools been developed to apply
this concept clinically.
The notion that surface electrocardiographic
events can be related to their intracardiac source has
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828existed for almost 50 years (82). Computing and the-
ory have advanced to the point that patient-speciﬁc
AF-maintaining mechanisms can be identiﬁed in
detail via noninvasive body-surface mapping by
electrocardiographic imaging (83). Recently, electro-
cardiographic imaging has been applied to target
ablation for persistent AF, resulting in abbreviated
ablation procedures with increased efﬁciency com-
pared with stepwise ablation (84).
Another approach to mechanism-targeted ablation
uses biatrial basket-catheter mapping, in combina-
tion with algorithms based on restitution data, to
identify focal sources and stable (for >10 min)
AF-maintaining rotors (77). The mean number of
concurrent sources per patient averages about 2, with
the number of sources increasing with AF-promoting
factors such as obstructive sleep apnea, LA enlarge-
ment, and left ventricular dysfunction (85). A
randomized multicenter trial has shown superior
sinus rhythm maintenance with this mechanism-
based approach compared with conventional AF
ablation (77).PREVENTION OF RECURRENCE
AND PROGRESSION
Recurrence of atrial tachyarrhythmia is a major
problem limiting the effectiveness of AF ablation. A
recent meta-analysis indicated an AF recurrence rate
of 31.2% after a mean follow-up of almost 2 years
post-ablation (86). The mechanisms of arrhythmiaeading circle
re refractory -core excitable
ends on balance
een ERP and CV
uced CV favors -reduced CV destabilizes
Spiral-wave rotor
-depends on excitability
properties
core
5 Comparison of Leading Circle and Spiral Wave
s of Re-Entry
leading-circle re-entry should establish itself in smaller circuits
þ-channel blockade, favoring AF, spiral-wave theory predicts rotor
ization, more consistent with clinical observations. CV ¼ conduction
; ERP ¼ effective refractory period.recurrence vary. For paroxysmal AF, the single most
important factor (particularly within the ﬁrst year
post-ablation) is PV reconnection, a return of PV
conduction after an initially successful PVI (Fig. 1G)
(87). Later recurrences appear to be related to
progression of the AF substrate (24,87).
Pharmacological maneuvers have been developed
to identify (during the initial PVI procedure)
“dormant” veins at risk of reconnecting, and to guide
additional ablation to prevent subsequent reconnec-
tion (Fig. 1G). Intravenous adenosine is widely used to
identify dormant conduction. RF ablation depolarizes
the resting membrane potential to levels at which
Naþ-channels are inactivated, producing inexcit-
ability. Adenosine hyperpolarizes PV cells by in-
creasing the background Kþ current (88). PVs that
recover excitability have less severe membrane
depolarization, and adenosine-induced hyperpolar-
ization is sufﬁcient to restore excitability and
conduction. In contrast, veins with more severe RF-
induced depolarization do not regain conduction
with adenosine (88). Adenosine hyperpolarizes PVs
more effectively than isoproterenol, and is more
likely to reveal dormant conduction (89). Adenosine-
guided ablation for drug-resistant paroxysmal AF has
been tested in a multicenter randomized controlled
trial (90). The preliminary results indicate that post-
PVI dormant PV conduction is associated with a
greater atrial tachyarrhythmia recurrence rate, and
eliminating dormant PV conduction by additional
targeted ablation reduces atrial tachyarrhythmia
recurrence by >50% (91).
The problem of substrate progression is multifac-
torial and challenging. Progression of atrial damage
due to underlying heart disease is a major factor (24).
Most risk factors affect AF by causing structural
remodeling (2). Recent work suggests that AF recur-
rence can be prevented by effectively managing risk
factors such as obstructive sleep apnea and obesity,
presumably by curtailing further damage and/or
reversing existing abnormalities (92–94).
Conversely, AF itself can cause progression of the
substrate (95). In addition to complex ion-channel
remodeling that accelerates repolarization and alters
conduction properties (95), rapid activation of atrial
cardiomyocytes causes proﬁbrotic changes in ﬁbro-
blast function and promotes atrial ﬁbrosis (96).
Recent work points to Ca2þ signaling as a key mech-
anism in AF progression (97).
The well-established therapeutic resistance of
longstanding AF appears to result from structural
alterations that greatly magnify the complexity of
underlying mechanisms and make it almost impos-
sible to successfully restore and maintain sinus
J A C C V O L . 6 4 , N O . 8 , 2 0 1 4 Nishida et al.
A U G U S T 2 6 , 2 0 1 4 : 8 2 3 – 3 1 Translational Research in AF Ablation
829rhythm (84,98). Early and aggressive sinus rhythm
maintenance may forestall such changes (99). Inter-
esting recent data suggest that effective mechanism-
directed ablation might prevent long-term recurrence
(100). Alternatively or additionally, work is needed to
develop safe, effective upstream pharmacological
therapies to suppress mechanisms leading to AF pro-
gression. To date, despite success in well-deﬁned
animal models (101), effective upstream therapy has
yet to be convincingly applied in humans (102).
Extensive additional basic and clinical research is
clearly needed before upstream therapy can become a
practical reality.
LIMITATIONS OF BASIC RESEARCH
It is important to recognize that all experimental
models, by their nature, are simpliﬁed paradigms
that interrogate speciﬁc questions in the absence of
clinical AF’s complexity. Thus, the results of
experimental studies need careful consideration,
and their predictions must be conﬁrmed by appro-
priate clinical research. Experimental models ofatrial ectopic activity, as may occur with both
PV and non-PV drivers (103), are very limited, and
only recently have insights into the mechanisms
underlying such ectopic activity been obtained
(104–106).
CONCLUSIONS
The development of successful AF ablation pro-
cedures has been marked by dynamic interplay be-
tween basic research and astute clinical application/
observation. Despite great progress to date, more
work is needed to ensure effective and enduring
management of AF in the broad and complex AF
population.
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